MX356760B - Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad. - Google Patents

Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.

Info

Publication number
MX356760B
MX356760B MX2012014905A MX2012014905A MX356760B MX 356760 B MX356760 B MX 356760B MX 2012014905 A MX2012014905 A MX 2012014905A MX 2012014905 A MX2012014905 A MX 2012014905A MX 356760 B MX356760 B MX 356760B
Authority
MX
Mexico
Prior art keywords
disease
treatment
methods
synthetic triterpenoids
triterpenoids
Prior art date
Application number
MX2012014905A
Other languages
English (en)
Inventor
Sporn Michael
Liby Karen
Honda Tadashi
M Kral Robert
J Meyer Colin
W Gribble Gordon
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX356760(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of MX356760B publication Critical patent/MX356760B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se trata de métodos para tratar y prevenir la nefropatía, resistencia a la insulina/diabetes, esteatosis hepática, y/o disfunción endotelial/enfermedad cardiovascular mediante el uso de triterpenoides sintéticos, opcionalmente en combinación con un segundo tratamiento o profilaxis.
MX2012014905A 2008-01-11 2009-01-12 Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad. MX356760B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2062408P 2008-01-11 2008-01-11
US10911408P 2008-10-28 2008-10-28
PCT/US2009/030771 WO2009089545A1 (en) 2008-01-11 2009-01-12 Synthetic triterpenoids and methods of use in the treatment of disease

Publications (1)

Publication Number Publication Date
MX356760B true MX356760B (es) 2018-06-12

Family

ID=40377326

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010007610A MX2010007610A (es) 2008-01-11 2009-01-12 Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
MX2012014905A MX356760B (es) 2008-01-11 2009-01-12 Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010007610A MX2010007610A (es) 2008-01-11 2009-01-12 Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.

Country Status (32)

Country Link
US (4) US8129429B2 (es)
EP (2) EP3492077A1 (es)
JP (3) JP4923146B2 (es)
KR (2) KR101780382B1 (es)
CN (3) CN108434151A (es)
AU (1) AU2009203941B2 (es)
BR (1) BRPI0907423A2 (es)
CA (3) CA2711834C (es)
CL (1) CL2009000048A1 (es)
CO (1) CO6351720A2 (es)
CY (1) CY1121531T1 (es)
DK (1) DK2252283T3 (es)
EA (1) EA022166B1 (es)
ES (1) ES2718047T3 (es)
HK (3) HK1148196A1 (es)
HR (1) HRP20190031T1 (es)
HU (1) HUE043175T2 (es)
IL (3) IL206749A0 (es)
LT (1) LT2252283T (es)
ME (1) ME03529B (es)
MX (2) MX2010007610A (es)
MY (1) MY158798A (es)
NZ (1) NZ586751A (es)
PH (2) PH12014500261A1 (es)
PL (1) PL2252283T3 (es)
PT (1) PT2252283T (es)
RS (1) RS58486B1 (es)
SG (1) SG187464A1 (es)
SI (1) SI2252283T1 (es)
TW (4) TWI492745B (es)
WO (1) WO2009089545A1 (es)
ZA (1) ZA201005117B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20080172026A1 (en) 2006-10-17 2008-07-17 Blomquist Michael L Insulin pump having a suspension bolus
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
US20090177147A1 (en) 2008-01-07 2009-07-09 Michael Blomquist Insulin pump with insulin therapy coaching
EP3492077A1 (en) 2008-01-11 2019-06-05 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
LT2276493T (lt) 2008-04-18 2019-01-10 Reata Pharmaceuticals, Inc. Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
DK2271658T3 (en) 2008-04-18 2017-02-06 Reata Pharmaceuticals Inc ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGED OLEANOLIC ACID DERIVATIVES
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
AU2009274037B2 (en) * 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
PT3254675T (pt) * 2009-02-13 2019-06-14 Reata Pharmaceuticals Inc Composições de dosagem oral de libertação prolongada que contêm cddo-me amorfo
US20100332254A1 (en) * 2009-06-26 2010-12-30 Michael Maschke In-vitro device support for x-ray based kidney function test
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
MY163031A (en) 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
AU2014208299B2 (en) * 2010-04-12 2015-10-01 Reata Pharmaceuticals, Inc. Method of treating obesity using antioxidant inflammation modulators
WO2011140078A1 (en) * 2010-05-04 2011-11-10 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
ES2653717T3 (es) 2010-12-17 2018-02-08 Reata Pharmaceuticals, Inc. Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación
EA026847B1 (ru) 2011-03-11 2017-05-31 Рита Фармасьютикалз, Инк. C4-монометилтритерпеноидные производные и способы их применения
WO2012154554A1 (en) * 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CA2869783C (en) 2012-04-27 2022-06-21 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9238100B2 (en) 2012-06-07 2016-01-19 Tandem Diabetes Care, Inc. Device and method for training users of ambulatory medical devices
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
LT2892911T (lt) 2012-09-10 2017-11-10 Reata Pharmaceuticals, Inc. Oleanolinės rūgšties c17 heteroarilo dariniai ir jų panaudojimo būdas
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CA2884400A1 (en) * 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
CA2882418C (en) 2012-09-10 2021-05-04 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US10357606B2 (en) 2013-03-13 2019-07-23 Tandem Diabetes Care, Inc. System and method for integration of insulin pumps and continuous glucose monitoring
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US10016561B2 (en) 2013-03-15 2018-07-10 Tandem Diabetes Care, Inc. Clinical variable determination
TW201514192A (zh) 2013-03-19 2015-04-16 Daiichi Sankyo Co Ltd 萜類衍生物
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
CN103340850A (zh) * 2013-07-05 2013-10-09 段仲达 Aphanamgrandiol A在制备治疗急性肾衰药物中的应用
CN103330704A (zh) * 2013-07-05 2013-10-02 严建低 Aphanamgrandiol A在制备治疗肾功能不全药物中的应用
IL285832B2 (en) * 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs
CN103494824B (zh) * 2013-10-21 2016-02-10 李英夫 Kadcoccitones A在制备治疗或预防急性心衰药物中的应用
CN103520181B (zh) * 2013-10-21 2016-02-17 青岛市市立医院 Phyllanthoid A在制备治疗和预防肾纤维化药物中的应用
CN103520172B (zh) * 2013-10-22 2016-02-24 陈延翠 Kadcoccitones A在制备治疗急性肾衰药物中的应用
CN103550225B (zh) * 2013-10-22 2016-01-27 青岛市市立医院 Phyllanthoid A在制备治疗或预防慢性心衰药物中的应用
CN103739653B (zh) * 2013-12-26 2016-08-31 中国科学院华南植物园 一种23-降齐墩果烷酸化合物及其制备方法和在制备糖苷酶抑制剂药物中的用途
US9290455B2 (en) 2014-02-11 2016-03-22 Trustees Of Dartmouth College CDDO-Me amino acid conjugates and methods of use
EP3174577A4 (en) 2014-07-30 2018-04-18 Tandem Diabetes Care, Inc. Temporary suspension for closed-loop medicament therapy
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US9896475B2 (en) 2014-08-26 2018-02-20 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
JP6644433B2 (ja) 2014-09-10 2020-02-12 第一三共株式会社 眼疾患治療用及び予防用徐放性医薬組成物
EP3212195A4 (en) 2014-10-31 2018-06-06 The Regents of The University of California Compositions and methods for treating hiv-associated cognitive dysfunction
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
EA038328B1 (ru) * 2015-02-12 2021-08-10 Рита Фармасьютикалз, Инк. Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
KR20180061251A (ko) 2015-09-23 2018-06-07 리아타 파마슈티컬즈, 아이엔씨. Il-17의 저해를 위한 c4-변형된 올레아놀산 유도체 및 다른 용도
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
WO2018017940A1 (en) * 2016-07-21 2018-01-25 Baylor College Of Medicine Use of betulinic acid for the treatment or prevention of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
RU2018136782A (ru) * 2016-10-13 2020-04-20 ВИВАЧЕЛЛ БИОТЕКНОЛОДЖИ ИСПАНИЯ Эс.Эл. Производные тритерпиноидов
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
CN106983723B (zh) * 2017-05-08 2018-08-21 重庆植恩药业有限公司 奥利司他脂质体及其制备方法和在抗肿瘤药物中的应用
CN107349210B (zh) * 2017-06-20 2021-05-18 大连理工大学 具有α-淀粉酶协同抑制活性的组合物
AU2019272960A1 (en) * 2018-05-24 2020-12-10 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
EP3807895A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood sugar with a metformin pharmaceutical composition
CA3103424A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood sugar with a gliflozin sodium-glucose cotransporter 2 inhibitor pharmaceutical composition
EP3841115A4 (en) * 2018-08-20 2022-08-24 University of Georgia Research Foundation, Inc. COMPOSITIONS AND METHODS FOR ENHANCING WHITE FAT TISSUE BROWNING
KR20210096162A (ko) 2018-11-27 2021-08-04 쿄와 기린 가부시키가이샤 의약 조성물
CA3163745A1 (en) * 2019-12-03 2021-06-10 Baylor College Of Medicine Therapeutic compounds for methods of use in insulin resistance
US20230255982A1 (en) 2020-05-09 2023-08-17 Reata Pharmaceuticals Holdings, LLC Methods of treating covid-19 using bardoxolone methyl or analogs thereof
CN114053281A (zh) * 2020-08-10 2022-02-18 成都文鼎科技发展有限公司 治疗慢性肾病的方法和药物组合物
EP4211120A1 (en) * 2020-09-14 2023-07-19 Triterpenoid Therapeutics, Inc. Analogs of cddo-2p-im and cddo-3p-im
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
CN116761628A (zh) * 2020-12-11 2023-09-15 江苏恒瑞医药股份有限公司 Jak抑制剂在肾脏疾病中的应用
CA3204434A1 (en) 2021-01-18 2022-07-21 Xin Jiang Synthetic ursolic acid derivatives and methods of use thereof

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) * 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL84842A0 (en) 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
ZA891076B (en) 1988-02-16 1990-10-31 Lilly Co Eli 2',3'-dideoxy-2',2'-difluoronucleosides
US5064823A (en) * 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JPH05505815A (ja) 1990-04-04 1993-08-26 ニユコメド・イメージング・アクシエセルカペト ヌクレオシド誘導体
JP2950616B2 (ja) 1991-01-29 1999-09-20 塩野義製薬株式会社 トリテルペン誘導体
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
UA41261C2 (uk) 1992-06-22 2001-09-17 Елі Ліллі Енд Компані Спосіб одержання збагачених бета-аномером нуклеозидів
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DE4308042C2 (de) * 1993-03-13 2000-10-12 Alstom Energy Syst Gmbh Wälzmühle
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5972703A (en) * 1994-08-12 1999-10-26 The Regents Of The University Of Michigan Bone precursor cells: compositions and methods
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
DK0909184T3 (da) 1996-07-03 2003-12-22 Upjohn Co Målrettet lægemiddelindgivelse ved anvendelse af sulfonamidderivater
HU224918B1 (en) 1997-01-24 2006-04-28 Conpharma As Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
WO1999040075A1 (fr) * 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Derives de sulfamide, leur procede de production et leur utilisation
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6485756B1 (en) * 1999-04-06 2002-11-26 Collaborative Technologies, Inc. Stable, homogeneous natural product extracts containing polar and apolar fractions
DE60036101T2 (de) 1999-05-14 2008-05-15 Nereus Pharmaceuticals, Inc., San Diego Interleukin-1 und tumornekrosefaktor-alpha modulatoren,synthese dieser modulatoren und methoden zur anwendung dieser modulatoren
ATE384952T1 (de) 1999-06-25 2008-02-15 Roche Diagnostics Operations Enzymhemmungsimmunverfahren
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) * 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
EP1322661A1 (en) 2000-09-29 2003-07-02 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
PL365285A1 (en) 2001-03-23 2004-12-27 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
AU2002308701A1 (en) 2001-05-14 2002-11-25 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
IL161785A0 (en) 2001-11-23 2005-11-20 Chugai Pharmaceutical Co Ltd Method for identification of tumor targeting enzymes
EP1465615B1 (en) * 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
DE60325329D1 (de) 2002-01-18 2009-01-29 Univ Minnesota Quaternäre terpensalze als biologisch aktive tenside
GB0204772D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
WO2004064723A2 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
CN103211806B (zh) 2003-05-27 2015-09-09 帝斯曼知识产权资产管理有限公司 新颖的营养药物性组合物及其用途
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
JP2005314381A (ja) * 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
WO2005113761A2 (en) 2004-04-19 2005-12-01 University Of Maryland, Baltimore Novel alanine transaminase enzymes and methods of use
US7765576B2 (en) * 2004-05-12 2010-07-27 Finsiar Corporation Changing communication mode in a CATV pathway using mute commands
JP5087400B2 (ja) 2004-09-07 2012-12-05 パシフィック アロー リミテッド アンゲロイル基を有する抗腫瘍化合物
GB0513079D0 (en) * 2005-06-28 2005-08-03 Univ Wales Bangor Improvements in and relating to plant pathogen resistance
WO2007005879A2 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
AU2006325586B2 (en) 2005-12-12 2013-01-31 Mosamedix B.V. Annexin derivatives suitable for pretargeting in therapy and diagnosis
WO2007103727A2 (en) 2006-03-03 2007-09-13 Savipu Pharmaceuticals Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of nf-kb
EP1996205A2 (en) 2006-03-23 2008-12-03 Advanced Life Sciences Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
WO2008000068A1 (en) 2006-06-27 2008-01-03 Wellington Laboratories Inc. Method for preparing 2-iodo triterpenoid compounds
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
JP2010510243A (ja) 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
EP2680009A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
EP3492077A1 (en) 2008-01-11 2019-06-05 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
LT2276493T (lt) 2008-04-18 2019-01-10 Reata Pharmaceuticals, Inc. Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17
DK2271658T3 (en) 2008-04-18 2017-02-06 Reata Pharmaceuticals Inc ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGED OLEANOLIC ACID DERIVATIVES
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CA2744388A1 (en) 2008-11-21 2010-05-27 The Johns Hopkins University Compositions and methods for treating or preventing radiation injury
PT3254675T (pt) 2009-02-13 2019-06-14 Reata Pharmaceuticals Inc Composições de dosagem oral de libertação prolongada que contêm cddo-me amorfo
MY163031A (en) 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
ES2653717T3 (es) 2010-12-17 2018-02-08 Reata Pharmaceuticals, Inc. Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación
EA026847B1 (ru) 2011-03-11 2017-05-31 Рита Фармасьютикалз, Инк. C4-монометилтритерпеноидные производные и способы их применения
CA2869783C (en) 2012-04-27 2022-06-21 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
CA2884400A1 (en) 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
CA2882418C (en) 2012-09-10 2021-05-04 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
LT2892911T (lt) 2012-09-10 2017-11-10 Reata Pharmaceuticals, Inc. Oleanolinės rūgšties c17 heteroarilo dariniai ir jų panaudojimo būdas
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
IL285832B2 (en) 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs

Also Published As

Publication number Publication date
EA201000984A1 (ru) 2011-02-28
HK1206593A1 (en) 2016-01-15
NZ586751A (en) 2012-08-31
JP2014218530A (ja) 2014-11-20
TW201602129A (zh) 2016-01-16
KR20170060173A (ko) 2017-05-31
JP5946873B2 (ja) 2016-07-06
ME03529B (me) 2020-04-20
CA2711834C (en) 2017-03-14
SI2252283T1 (sl) 2019-02-28
TWI621624B (zh) 2018-04-21
IL206749A0 (en) 2010-12-30
JP4923146B2 (ja) 2012-04-25
CL2009000048A1 (es) 2009-11-20
TW201216958A (en) 2012-05-01
EP2252283B9 (en) 2019-03-20
KR101780382B1 (ko) 2017-10-10
PH12014500261B1 (en) 2019-02-04
JP2012041353A (ja) 2012-03-01
KR20100117072A (ko) 2010-11-02
ES2718047T3 (es) 2019-06-27
CA2955987A1 (en) 2009-07-16
US8455544B2 (en) 2013-06-04
LT2252283T (lt) 2019-03-25
IL243538A0 (en) 2016-02-29
MY158798A (en) 2016-11-15
MX2010007610A (es) 2010-12-14
BRPI0907423A2 (pt) 2020-10-27
EP2252283A1 (en) 2010-11-24
US20180161311A1 (en) 2018-06-14
EP2252283B1 (en) 2018-11-28
CN108434151A (zh) 2018-08-24
IL243537A0 (en) 2016-02-29
PH12016502474A1 (en) 2018-03-05
CA2955987C (en) 2020-01-07
TW201322977A (zh) 2013-06-16
TWI492745B (zh) 2015-07-21
HRP20190031T1 (hr) 2019-04-19
HK1148196A1 (en) 2011-09-02
IL243538B (en) 2020-05-31
CN101965184A (zh) 2011-02-02
PT2252283T (pt) 2019-01-23
EP3492077A1 (en) 2019-06-05
TW200942231A (en) 2009-10-16
DK2252283T3 (en) 2019-01-28
SG187464A1 (en) 2013-02-28
CN101965184B (zh) 2015-03-11
RS58486B1 (sr) 2019-04-30
HK1258817A1 (zh) 2019-11-22
ZA201005117B (en) 2016-07-27
US8129429B2 (en) 2012-03-06
CO6351720A2 (es) 2011-12-20
US20090326063A1 (en) 2009-12-31
HUE043175T2 (hu) 2019-08-28
JP2011509941A (ja) 2011-03-31
US20120220652A1 (en) 2012-08-30
AU2009203941A1 (en) 2009-07-16
KR101880692B1 (ko) 2018-07-20
PH12014500261A1 (en) 2019-02-04
US9757359B2 (en) 2017-09-12
US20130345276A1 (en) 2013-12-26
PL2252283T3 (pl) 2019-09-30
JP5608143B2 (ja) 2014-10-15
EA022166B1 (ru) 2015-11-30
CN104739841B (zh) 2018-06-01
CY1121531T1 (el) 2020-05-29
WO2009089545A1 (en) 2009-07-16
CA3062806A1 (en) 2009-07-16
CA2711834A1 (en) 2009-07-16
CN104739841A (zh) 2015-07-01
CA3062806C (en) 2022-09-13
AU2009203941B2 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
PH12016502474A1 (en) Synthetic triterpenoids and methods of use in the treatment of disease
SI2358697T1 (sl) Spojine izoindolina za uporabo pri zdravljenju raka
MY172372A (en) Compositions and methods for lowering triglycerides
AP3856A (en) Improvements in feedwells.
ZA201001442B (en) Combination therapy with type i and type ii anti-cd20 antibodies
IL212668A0 (en) Treatment with alpha 7-selective ligands
EP2249861A4 (en) TREATMENT OF NEURODEEGENERATIVE DISEASES WITH PROGRANULIN (PGRN)
AU316080S (en) A lid with attached utensil
BRPI0909818A2 (pt) métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
ZA200903837B (en) Use of 3-Alpha-androstanediol, optionally in combination with A-5-HT1A agonist, in the treatment of sexual dysfunction
PL2564872T3 (pl) Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości
PL2370070T3 (pl) Pimobendan do zastosowania w leczeniu kardiomiopatii przerostowej u kotów
IL207647A0 (en) Use of interleukin-1 conjugates in the treatment of diabetes
EP2213386A4 (en) METHOD FOR WASHING A CYANO-CONTAINING FERTILIZER AND MICRO-ORGANISM FOR USE IN THE WASHING PROCESS
UA99332C2 (en) Herbicidal combinations having diflufenican and pinoxaden and use thereof
CA117571S (en) Tea pot
AU312299S (en) Circular saw
TN2011000206A1 (en) Compositions and methods of use soluble thrombomodulin variants
WO2010007528A3 (en) Biomarkers for insulin efficacy
AU322839S (en) A spreader unit
TH111733B (th) สารผสมทรีตผิวโลหะ, และวัสดุโลหะที่มีการทรีตผิวด้วยฟิล์มทรีตผิวโลหะที่เตรียมได้จากสารผสมทรีตผิวโลหะนี้
UA27342U (en) Method for preventing pre-eclampsia in pregnants with chronic renal diseases
UA37388U (uk) Засіб для лікування серцево-судинних захворювань для парентерального застосування
WO2009135939A3 (en) Pm02734 for use in the treatment of ewing' s sarcoma, osteosarcoma, rhabdomyosarcoma and medulloblastoma
AU320226S (en) Foot for a brace